CS
ITOS

Credit Suisse’s iTeos Therapeutics ITOS Stock Holding History

Credit Suisse’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$364K Hold
26,661
– – ﹤0.01% 2765
2023
Q4 		$292K Buy
26,661
+7,756
+41% +$76.9K ﹤0.01% 2921
2023
Q3 		$207K Sell
18,905
-4,512
-19% -$57.7K ﹤0.01% 3023
2023
Q2 		$310K Buy
23,417
+553
+2% +$7.88K ﹤0.01% 2995
2023
Q1 		$311K Buy
22,864
+1,608
+8% +$28.8K ﹤0.01% 2983
2022
Q4 		$415K Sell
21,256
-539
-2% -$10.5K ﹤0.01% 2889
2022
Q3 		$415K Buy
21,795
+12,605
+137% +$290K ﹤0.01% 2901
2022
Q2 		$189K Sell
9,190
-1,117
-11% -$26.5K ﹤0.01% 3352
2022
Q1 		$331K Sell
10,307
-1,195
-10% -$43.4K ﹤0.01% 3178
2021
Q4 		$535K Buy
+11,502
New +$383K ﹤0.01% 3766
2021
Q2 		– Sell
-8,912
Closed -$304K – 4529
2021
Q1 		$304K Sell
8,912
-24,584
-73% -$888K ﹤0.01% 3990
2020
Q4 		$1.13M Buy
+33,496
New +$887K ﹤0.01% 3249

Other funds holding ITOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Credit Suisse's ITOS Position: Q1 2024 in Review

Credit Suisse held its iTeos Therapeutics (ITOS) position steady in Q1 2024 at 26,661 shares worth $364K. The position accounts for ﹤0.01% of the portfolio, ranked #2765.

Credit Suisse first reported a position in ITOS in Q4 2020 and has held it in 12 quarters since. The position peaked at $1.13M in Q4 2020. 136 funds tracked by Wall St. Rank hold ITOS as of Q1 2024.

  • Credit Suisse held 26,661 shares of iTeos Therapeutics worth $364K as of Q1 2024.
  • Credit Suisse left its iTeos Therapeutics share count unchanged in Q1 2024.
  • iTeos Therapeutics made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2765 holding.
  • Credit Suisse first reported a position in iTeos Therapeutics in Q4 2020 and has held it in 12 quarters since.
  • Credit Suisse's iTeos Therapeutics position peaked at $1.13M in Q4 2020.
  • 136 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.